



Universiteit
Leiden
The Netherlands

Juvenile Idiopathic Arthritis: Towards Improving Clinical Care

Hissink Muller, P.

Citation

Hissink Muller, P. (2019, October 31). *Juvenile Idiopathic Arthritis: Towards Improving Clinical Care*. Retrieved from <https://hdl.handle.net/1887/80001>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/80001>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/80001> holds various files of this Leiden University dissertation.

Author: Hissink Muller, P.

Title: Juvenile Idiopathic Arthritis: Towards Improving Clinical Care

Issue Date: 2019-10-31

Anticarbamylated protein (anti-CarP) antibodies are present in sera of Juvenile Idiopathic Arthritis (JIA) patients

P. C. E. Hissink Muller*, J. Anink*, J. Shi*, E.W.N. Levarht, T. H. Reinards, M. H. Otten, M. J. D. van Tol, C.M. Jol-van der Zijde, D.M.C. Brinkman, C. F. Allaart, E. P. Hoppenreijns, Y. Koopman-Keemink, S. Kamphuis, K. Dolman, J. M. van den Berg, M.A.J. van Rossum, L. W.A. van Suijlekom-Smit, M. W. Schilham, T.W.J. Huizinga, R. E. M. Toes, R. ten Cate, L. A. Trouw

Published in Annals of the Rheumatic Diseases, 2013;72:2053–2055

* P. C. E. Hissink Muller, J. Anink and J. Shi contributed equally to this study

Key words: Juvenile Idiopathic Arthritis, anti-CarP antibodies, anti-citrullinated protein antibodies.

In Juvenile Idiopathic Arthritis (JIA) patients there is a lack of markers that predict severe disease. Although anti-citrullinated protein antibodies (ACPA) have contributed substantially to the understanding of Rheumatoid Arthritis (RA)¹, their detection in JIA has not been equally useful as incidence rates in JIA patients are low² and merely confined to the polyarticular IgM-RF positive category resembling RA. Recently, anti-carbamylated protein antibodies (anti-CarP) were detected in 45% of RA patients and importantly also in 16-20% ACPA-negative patients³⁻⁵. Within the ACPA-negative patients, anti-CarP antibodies were associated with more severe radiographic progression³. Since most JIA patients are ACPA-negative we investigated whether anti-CarP antibodies are present in sera of JIA patients and how they are related to ACPA and IgM-RF.

JIA patients from three Dutch sources were included: the *BeSt for Kids trial* (NTR 1574, a treatment strategy study) (n=33), a previously described cohort⁶ (n=48) and the Arthritis and Biologicals in Children (ABC) Register⁷ (n=153). Healthy controls (n=107) (mean age/range 11/(2-20)) are stem-cell graft donors. Written informed consent was obtained from all patients and controls. Blood collection and storage are comparable among different cohorts. Cross-sectionally obtained sera from 234 JIA patients at variable time points in disease course were analyzed. All ILAR JIA categories were included⁸ with polyarticular JIA overrepresented. Median disease duration at the time of serum collection was 2.3 years (IQR 0.7-6.8) (Table 1). Patients' disease characteristics were collected from patient files. Anti-CarP and ACPA antibodies were measured by ELISA as described previously.³

Table 1 | Disease characteristics of 234 JIA patients

Characteristics	Number
Gender m/f (%f)	76/158 (67,5%)
Median age (years) (IQR)	12.1 (8.4-16.2)
Median disease duration (IQR)	2.3 (0.7-6.8)
Median age at JIA onset (IQR)	8.8 (3.4-12.4)
ANA positive at disease onset	64 (27,4%)
Systemic JIA	35 (15,0%)
Poly-articular JIA RF negative	90 (38.5%)
Poly-articular JIA RF positive	19 (8,1%)
Oligo-articular JIA extended	41 (17,5%)
Oligo-articular JIA persistent	18 (7.7%)
Juvenile Psoriatic Arthritis	24 (10,3%)
Enthesitis Related Arthritis	5 (2.1%)
Undifferentiated	2 (0.8%)

We observed that 8.1% (19/234) of the JIA patients were positive for anti-Ca-FCS antibodies versus 4.7% (5/107) of controls ($p=0.20$); 13.2% (31/234) of patients vs 2.8% (3/107) of controls were positive for anti-Ca-Fib antibodies ($p=0.003$); 16.7% (39/234) of patients vs 8/107 (7.5%) of controls were positive for at least one anti-CarP antibody ($p=0.028$); 11/234 (4.7%) vs 0 of controls ($p=0.017$) were positive for both anti-CarP reactivities. Both anti-Ca-FCS and anti-Ca-Fib antibodies were predominantly present in polyarticular IgM-RF positive patients compared to other JIA categories ($p<0.0001$) (Figure 1). Additionally 53% (8/15) of ACPA-positive patients and 42.1% (8/19) of IgM-RF-positive patients were also




Figure 1 | IgG anticarbamylated protein (anti-CarP) antibodies are present in juvenile idiopathic arthritis (JIA) sera. A cut-off for positivity(horizontal line) was determined using the mean plus two times the SD of the healthy controls. Antibodies against Ca-FCS (A) and Ca-Fib (B) in the sera of JIA patients and healthy controls are depicted in aU/mL. (C) Results of anti-CarP antibodies: positivity above cut-off per JIA category in absolute number, percentage and significance (NS, not significant, * $p<0.05$, ** $p<0.01$). FCS, fetal calfs serum; RF, rheumatoid factor.

positive for anti-CarP antibodies. Importantly, anti-CarP antibodies were also found in ACPA and IgM-RF-negative patients as 57,9% (11/19) of anti-CarP positive patients were negative for ACPA and 27,3% (3/11) were negative for IgM-RF. In total 9 JIA patients were positive for IgM-RF, ACPA and anti-CarP (Ca-FCS and/or Ca-Fib) antibodies. All triple positive patients were part of the ABC-register.

Disease duration at sample collection, ANA status or age were not associated with the presence of anti-CarP antibodies. In the second cohort⁶ we did not find an association of anti-CarP positivity with disease activity measured by time-in-active-disease at the time of sampling. Within the ABC-register cohort no association was found between the presence of anti-CarP antibodies and ACR-Pedi 30 response⁹ or reaching inactive disease¹⁰ at 15 months after start of anti-TNF treatment. The cross-sectional nature of these three cohorts did not allow a more in depth analysis on association with clinical outcome.

This is the first study showing the presence of anti-CarP antibodies in JIA stimulating future studies on the diagnostic and prognostic value of anti-CarP antibodies in JIA.

Competing Interest: None declared.

REFERENCES

- 1 Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. *Lancet* 2010;376:1094-1108.
- 2 Syed RH, Gilliam BE, Moore TL. Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology. *Curr Rheumatol Rep* 2008;10:156-163.
- 3 Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. *Proc Natl Acad Sci U S A* 2011;108:17372-17377.
- 4 Shi J, van de Stadt LA, Levarht EW, et al. Brief report: anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. *Arthritis Rheum* 2013;65:911-915.
- 5 Trouw LA, Huizinga TW, Toes RE. Autoimmunity in rheumatoid arthritis: different antigens--common principles. *Ann Rheum Dis* 2013;72 Suppl 2:ii132-ii136.
- 6 Albers HM, Brinkman DM, Kamphuis SS, et al. Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis. *Arthritis Care Res (Hoboken)* 2010;62:204-212.
- 7 Otten MH, Prince FH, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. *JAMA* 2011;306:2340-2347.
- 8 Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. *J Rheumatol* 1998;25:1991-1994.
- 9 Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. *Arthritis Rheum* 1997;40:1202-1209.
- 10 Wallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. *Arthritis Care Res (Hoboken)* 2011;63:929-936.

